TuisAMPH • NASDAQ
add
Amphastar Pharmaceuticals Inc
Vorige sluiting
$18,18
Dagwisseling
$17,81 - $18,46
Jaarwisseling
$17,03 - $31,26
Markkapitalisasie
824,83 m USD
Gemiddelde volume
541,92 k
P/V-verhouding
8,93
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 183,10 m | -1,83% |
Bedryfskoste | 50,06 m | 20,62% |
Netto inkomste | 24,43 m | -35,65% |
Netto winsgrens | 13,34 | -34,45% |
Wins per aandeel | 0,73 | -20,65% |
EBITDA | 49,95 m | -14,74% |
Effektiewe belastingkoers | 23,45% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 282,81 m | 27,60% |
Totale bates | 1,63 mjd | 3,29% |
Totale aanspreeklikheid | 840,49 m | -0,55% |
Totale ekwiteit | 788,80 m | — |
Uitstaande aandele | 45,37 m | — |
Prys om te bespreek | 1,05 | — |
Opbrengs op bates | 5,40% | — |
Opbrengs op kapitaal | 6,18% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 24,43 m | -35,65% |
Kontant van bedrywe | 32,86 m | 13,23% |
Kontant van beleggings | -60,57 m | -69,77% |
Kontant van finansiering | -18,37 m | 45,71% |
Netto kontantverandering | -46,09 m | -13,78% |
Beskikbare kontantvloei | -4,75 m | -118,35% |
Meer oor
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
Gestig
1996
Webwerf
Werknemers
1 976
